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Abstract: Isotretinoin, a drug used for moderate to severe acne, has been repeatedly 
associated with various psychiatric complications, although a definitive causal relationship 
has not been established to date. This case report describes a 25-year-old male who developed 
 obsessive-compulsive disorder at the age of 23 years following isotretinoin treatment for 
acne (10–20 mg/day) since the age of 16 years. Although standard treatment for  obsessive-
compulsive disorder caused mood swings, the combination of fluvoxamine 300 mg/day 
and olanzapine 15 mg/day significantly improves the clinical picture. Although rare, severe 
adulthood psychiatric complications may occur following isotretinoin treatment, requiring 
management which is individually tailored to the patient.
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Introduction
Isotretinoin is a systemic synthetic retinoid used to treat moderate to severe  nodulocystic 
acne vulgaris that is not responding to other therapies, as well as a number of other 
dermatologic diseases, including psoriasis, hidradenitis suppurativa, ichthyosis, lesions 
associated with lupus erythematosus, some cases of severe acne rosacea, and various 
skin cancers, or even adjunctive therapy for acute promyelocytic leukemia.1
Among other adverse effects, isotretinoin has repeatedly been associated with 
depression, suicidality, and psychotic symptoms, although the link between isotretinoin 
use and psychiatric events remains controversial.2
Remarkably, when affective psychosis and obsessive-compulsive disorder (OCD) 
occur following isotretinoin treatment, associated psychopathology is generally severe 
and eventually poorly responsive to conventional treatment, as highlighted by recent, 
large, retrospective studies.3 Also, although patients suffering from bipolar disorder may 
be at increased risk for mood symptom exacerbations due to isotretinoin therapy, includ-
ing suicidal ideation, even with a concurrent antimanic therapy,3 less is known about the 
risk for developing ex novo affective psychosis and antidepressant manic vulnerability 
when isotretinoin treatment is used during adolescence. Furthermore, acne itself often 
occurs during adolescence, and can be eventually induced by lithium, a standard treat-
ment for bipolar disorder, which, in turn, usually has its onset at the same age.
Case report
A 25-year-old Caucasian male came to his first psychiatric consultation at the age of 
23 years at the suggestion of his general practitioner due to complaints about intrusive 
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obsessive thoughts starting about one year earlier.  Obsessive 
symptoms essentially consisted of self-reproachment about 
his “ineptitude” in sitting academic examinations and 
 consequent overwhelming feelings of guilt toward his par-
ents. There were no associated physical problems, although 
he reported a history of severe acne vulgaris that had been 
successfully treated by a dermatologist with isotretinoin 
10 mg/day since the age of about 16 years.
Initial evaluation led to a diagnosis of OCD, after 
excluding a personal or family history for psychiatric 
 disorders. Diagnosis was also made on the basis of the Mini 
International Neuropsychiatric Interview4 and Yale-Brown 
Obsessive-Compulsive Scale,5 the total score for which 
was 26 ($24 indicates severe OCD). He was prescribed 
 fluvoxamine 100 mg/day, having agreed to the proposal 
of dose augmentation within the following weeks. Two 
weeks later he had an unexpected precocious response with 
a marked ego-dystonic reaction, so current therapy was 
maintained. More surprisingly, two weeks later, intrusive 
thoughts reappeared, now associated with loss, concomi-
tant intractable delusions of grandeur, flight of ideas, and 
an increase in goal-directed activity (eg, a sudden desire 
to start guitar lessons and to leave law school to become a 
theatrical agent). A diagnosis of mixed state with psychotic 
features was made on the basis of a Young Mania Rating 
Scale6 total score of 24 ($12 indicates mania, although 
mixed state assessment may be roughly  estimated). Therapy 
was then revised, halving the antidepressant dose and adding 
1200 mg/day of carbamazepine (lithium, a neuroprotective 
antisuicidal drug having the potential to worsen psoriasis, 
and typical antipsychotic augmentation options being disre-
garded due to a likely lack of compliance and the patient’s 
concerns about potential dermatologic recurrences). Despite 
the proposal of cognitive behavioral therapy augmentation 
or other nonpharmacologic interventions, the patient refused 
to take advantage of any therapy likely to be free of side 
effects, apparently for compliance reasons. After a further 
month the patient had a relapse of obsessive symptoms, with 
a substantial persistence of elation (despite considerably 
high carbamazepine serum levels, usually increasing by up 
to 60% in case of fluvoxamine coadministration), so he was 
prescribed fluvoxamine 25 mg/day and olanzapine 5 mg/
day. Doses were then increased every three weeks, reaching 
a final amount of 300 mg/day and 15 mg/day, respectively. 
Both obsessive and mood symptoms progressively remitted 
until almost complete resolution was observed six months 
later.
Discussion
Patients with OCD and related disorders, eg, body dysmor-
phic disorder, may have excessive concern about minor 
variations in skin color or texture, ordinary moles, or  thinning 
hair.7 A minority of cases, eg, some patients with severe 
psychotic body dysmorphic disorder and acne vulgaris, may 
abuse dermatologic drugs and cosmetics to inhibit normal 
seborrhea, as in the “Dorian Gray syndrome” (dream of 
eternal youth), eventually increasing the risk of long-term 
development of other psychiatric disorders, including 
 affective psychosis.8
On the other hand, acne, alopecia areata, atopic dermatitis, 
and psoriasis may be associated with psychiatric conditions 
such as depression and suicidal ideation, as well as with the 
use of some psychotropic medications, possibly suggesting 
a substantial immunoneuroendocrine overlap.9
Nonetheless, when a psychiatric comorbidity is diagnosed, 
patients seeking dermatologic care may interpret a suggestion 
to see a psychiatrist as indicating that the dermatologist thinks 
they are “crazy” or wants to get rid of them, thereby further 
reducing the chance of appropriate treatment.
Concerning the relationship between isotretinoin and the 
potential for subsequent onset of psychopathology, positive 
dechallenge and rechallenge cases have been reported, 
prompting physicians to look out for the onset or worsening 
of psychiatric symptoms, including bipolar disorder.10,13 
Nonetheless, the neurotoxicity of the synthetic retinoic acid 
analogs is supported by a considerable body of literature.
In fact, retinoids may lead to a decrease in dopaminergic 
orbitofrontal functioning via their effect on the hippocampus, 
which modulates dopaminergic function in the medial pre-
frontal cortex. Retinoic acid-induced deficits in hippocampal 
function may lead to a downstream effect on orbitofrontal 
function. However, evidence regarding the effects of retinoic 
acid in the serotonin pathways is controversial, although 
higher doses have resulted in decreased or complete loss 
of serotonergic neurons.1 This finding has psychiatric 
implications because the prefrontal dopaminergic imbalance 
may be closely associated with depression.
Recent evidence from positron emission tomography 
studies in human subjects showed isotretinoin to be 
associated with a decrease in orbitofrontal metabolism, which 
is known to play a major role in the symptomatology of both 
OCD and bipolar disorder. In fact, the molecular components 
required for retinoic acid signaling are expressed in the adult 
brain, and the overlap of brain areas implicated in retinoic 
acid function, stress, and depression suggests that retinoids 
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could play a role in affective and anxiety disorders,14 which 
are often comorbid.
In this case, the choice of the selective serotonin 
reuptake inhibitor fluvoxamine was based on its proven 
efficacy in OCD and on its modulatory effects on σ-1 
receptors, which might increase the antipsychotic effect of 
atypical antipsychotic drugs, possibly contributing to the 
early psychotic resolution showed by the patient described 
here.15,16 Naturally occurring neurosteroids, as well as many 
psychotropic drugs, bind to σ-receptors, which may mediate 
some neuroprotective action, including mood and cognition 
improvement.17,18
Although olanzapine and other atypical antipsychotic aug-
mentation strategies for selective serotonin reuptake inhibitor-
refractory, psychotic OCDs and/or concomitant mood disorder 
are supported by an increasing body of literature,19,20 the choice 
of a single agent is often difficult.21 Given their higher affin-
ity for 5-HT
2A
 receptors than for dopamine receptors, it has 
been speculated that atypical antipsychotics may induce OCD, 
even at low doses, due to high 5-HT
2A
 antagonism, whereas 
improvement is thought to occur only at high doses in response 
to high dopaminergic antagonism.22
The choice of olanzapine augmentation for  fluvoxamine 
therapy was also suggested by pharmacokinetic considerations. 
Fluvoxamine increases the olanzapine plasma concentration 
by approximately two-fold via CYP1A2  inhibition. On the 
other side, the alternative strategy of adding carbamazepine 
(even at low doses) to fluvoxamine and olanzapine was 
 discounted for compliance reasons. Moreover, the patient did 
not originally show a satisfactory response to this  antiepileptic 
drug even at 1200 mg/day (whereas olanzapine was indeed 
more effective, especially in reducing psychotic features). 
There were also pharmacokinetic considerations in the 
decision not to add carbamazepine, because it increases the 
renal clearance of olanzapine by about 45% and reduces 
the half-life of olanzapine by about 20%.23
In this case, the unusually rapid exacerbation on 
 anti depressants, as well as the presence of plausible iatrogenic-
induced depression with flights of ideas,24 pointed to a bipolar 
diathesis related to previous treatment with isotretinoin, 
suggesting the switch to an atypical antipsychotic that is 
associated with a rapid positive antipsychotic response.
Indeed, antidepressant lability could occur even without 
any previous or current isotretinoin exposure, and it may be 
difficult to discriminate whether mood switches and rapid 
exacerbation phenomena are due to isotretinoin or not. It is 
noteworthy that the patient had no prior familial or personal 
predictors of bipolar disorder, including during adolescence, 
which is the usual age of onset. Moreover, in this case it is 
remarkable that even a considerable dose of carbamazepine 
was not able to prevent the mood switch. Also, the use 
of  antidepressants such as fluvoxamine in the course of 
mixed states is debatable, although they are apparently well 
 established in the management of OCD symptoms.
Although the demonstration of a definitive causal 
relationship between isotretinoin use and increased risk 
for subsequent OCD development characterized by iatro-
genic vulnerability for affective psychosis is beyond the 
scope of this report, the modern pathogenic concept of the 
vulnerability stress model25 (with isotretinoin considered an 
essential stress factor) of psychiatric disease may prompt 
further controlled research on this association.
Finally, in addition to the suggestion of a relationship 
between isotretinoin and psychiatric disorders, this case 
report suggests that we should consider carefully both 
the course of illness and psychopharmacologic choices 
for patients reporting long-term use of isotretinoin during 
 adolescence and complicated by OCD.
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